Recognition and pathological features of periampullary region adenocarcinoma with an indeterminable origin.


Journal

Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310

Informations de publication

Date de publication:
06 2021
Historique:
received: 10 01 2021
accepted: 09 02 2021
pubmed: 20 5 2021
medline: 18 12 2021
entrez: 19 5 2021
Statut: ppublish

Résumé

Determination of the primary tumor in periampullary region carcinomas can be difficult, and the pathological assessment and clinicopathological characteristics remain elusive. In this study, we investigated the current recognition and practices for periampullary region adenocarcinoma with an indeterminable origin among expert pathologists through a cognitive survey. Simultaneously, we analyzed a prospective collection of cases with an indeterminable primary tumor diagnosed from 2008 to 2018 to elucidate their clinicopathological features. All cases with pathological indeterminable primary tumors were reported and discussed in a clinicopathological conference to elucidate if it was possible to distinguish the primary tumor clinically and pathologically. From the cognitive survey, over 85% of the pathologists had experienced cases with indeterminable primary tumors; however, 70% of the cases was reported as pancreatic cancer without definitive grounds. Interpretation of the main tumor mass varied, and no standardized method was developed to determine the primary tumor. During a prospective study, 42 of the 392 periampullary carcinoma cases (10.7%) were considered as tumors with a pathological indeterminable origin. After the clinicopathological conferences, 21 (5.4%) remained indeterminable and were considered final indeterminable cases. Histological studies showed that the tumors spread along both the bile duct and main pancreatic duct; this was the most representative finding of the final indeterminable cases. This study is the first to elucidate and recognize the current clinicopathological features of periampullary region adenocarcinomas with an indeterminable origin. Adequate assessment of primary tumors in periampullary region carcinomas will help to optimize epidemiological data of pancreatic and bile duct cancer.

Identifiants

pubmed: 34008914
doi: 10.1002/cam4.3809
pmc: PMC8178491
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3499-3510

Informations de copyright

© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Références

Arch Pathol Lab Med. 2015 Jul;139(7):848-57
pubmed: 26125425
Am J Surg Pathol. 2001 May;25(5):579-86
pubmed: 11342768
Mod Pathol. 2003 Sep;16(9):902-12
pubmed: 13679454
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
N Engl J Med. 2011 Aug 25;365(8):768-9; author reply 769
pubmed: 21864184
Cancer Med. 2016 Jan;5(1):88-99
pubmed: 26645826
Semin Diagn Pathol. 2012 Aug;29(3):127-41
pubmed: 23062420
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
Mod Pathol. 2016 Nov;29(11):1358-1369
pubmed: 27469329
Jpn J Clin Oncol. 2013 May;43(5):492-507
pubmed: 23493744
Ann Diagn Pathol. 1999 Apr;3(2):75-80
pubmed: 10196386
PLoS One. 2016 Nov 9;11(11):e0166067
pubmed: 27829047
Langenbecks Arch Surg. 2018 Dec;403(8):917-932
pubmed: 30397779
Pathol Int. 2005 Apr;55(4):180-8
pubmed: 15826244
Cancer Manag Res. 2019 Dec 30;11:10871-10882
pubmed: 31920396
Ann Surg Oncol. 2018 Apr;25(4):845-847
pubmed: 28752469
J Gastroenterol. 2014 Jan;49(1):64-72
pubmed: 23616173
Pathol Int. 2013 Aug;63(8):415-8
pubmed: 23957917
Ann Oncol. 2009 Jan;20(1):146-59
pubmed: 18667395
Am J Surg Pathol. 2000 Apr;24(4):493-504
pubmed: 10757396
PLoS One. 2015 Feb 23;10(2):e0118220
pubmed: 25706130

Auteurs

Ryuji Komine (R)

Department of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital East, Chiba, Japan.
Course of Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, Tokyo, Japan.

Motohiro Kojima (M)

Division of Pathology, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center Hospital East, Chiba, Japan.

Genichiro Ishi (G)

Division of Pathology, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center Hospital East, Chiba, Japan.

Masashi Kudo (M)

Department of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital East, Chiba, Japan.

Motokazu Sugimoto (M)

Department of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital East, Chiba, Japan.

Shin Kobayashi (S)

Department of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital East, Chiba, Japan.

Shinichiro Takahashi (S)

Department of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital East, Chiba, Japan.

Masaru Konishi (M)

Department of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital East, Chiba, Japan.

Tatsushi Kobayashi (T)

Department of Diagnostic Radiology, National Cancer Center Hospital East, Chiba, Japan.

Tetsuo Akimoto (T)

Course of Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Department of Radiation Oncology, National Cancer Center Hospital East, Chiba, Japan.

Ayumi Murakami (A)

Department of Pathology, Saiseikai Yokohamashi Nanbu Hospital, Kanagawa, Japan.

Motoko Sasaki (M)

Department of Human Pathology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan.

Mariko Tanaka (M)

Department of Pathology, University of Tokyo, Tokyo, Japan.

Akiko Matsuzaki (A)

Department of Pathology, University of the Ryukyus, Okinawa, Japan.

Nobuyuki Ohike (N)

Division of Pathology, Shizuoka Cancer Center, Shizuoka, Japan.

Katsunori Uchida (K)

Department of Pathology, Mie University, Mie, Japan.

Tomoko Sugiyama (T)

Department of Pathology, Tokai University School of Medicine, Kanagawa, Japan.

Kenichi Hirabayashi (K)

Department of Pathology, Tokai University School of Medicine, Kanagawa, Japan.

Takuma Tajiri (T)

Department of Pathology, Tokai University School of Medicine, Kanagawa, Japan.

Kazuyuki Ishida (K)

Department of Diagnostic Pathology, Dokkyo Medical University, Tochigi, Japan.

Keita Kai (K)

Department of Pathology, Saga University Hospital, Saga, Japan.

Yuko Omori (Y)

Department of Investigative Pathology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.

Kenji Notohara (K)

Department of Pathology, Kurashiki Central Hospital, Okayama, Japan.

Hiroshi Yamaguchi (H)

Department of Pathology, Saitama Medical University, Saitama, Japan.

Yoko Matsuda (Y)

Department of Pathology, Kagawa University, Kagawa, Japan.

Yoshiki Naito (Y)

Department of Diagnostic Pathology, Kurume University Hospital, Fukuoka, Japan.

Yuki Fukumura (Y)

Department of Human Pathology, School of Medicine, Juntendo University, Tokyo, Japan.

Yoshihiro Hamada (Y)

Department of Pathology, Fukuoka University, Fukuoka, Japan.

Yumi Mihara (Y)

Department of Pathology, National Hospital Organization Nagasaki Medical Center Hospital, Nagasaki, Japan.

Yohei Masugi (Y)

Department of Pathology, Keio University School of Medicine, Tokyo, Japan.

Naoto Gotohda (N)

Department of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital East, Chiba, Japan.
Course of Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, Tokyo, Japan.

Kenichi Harada (K)

Department of Human Pathology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan.

Noriyoshi Fukushima (N)

Department of Pathology, Jichi Medical University, Tochigi, Japan.

Toru Furukawa (T)

Department of Investigative Pathology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH